Dysmenorrhea Treatment Market Overview:
Cramping during a period causes excruciating agony that extends from the lower abdomen to the back, this, and the legs. In the first few years of adolescence, many women begin to experience dysmenorrhea, or acute pain, about five years after the beginning of their menstrual cycle. The treatment used to address the issue is known as the dysmenorrhea treatment market.
A recent analysis by Market Research Community predicted that the market for drugs used to treat dysmenorrhea treatment market will increase from USD XX billion in 2021 to USD XX billion in 2030.
North America, Europe, Asia-Pacific, and Latin America are the four regions into which the market is divided. Over the forecast period of 2022–2030, the market for treatments for dysmenorrhea is anticipated to grow significantly, with a CAGR of about 8.3%. This is despite a significant decline in product sales during the initial stages of pandemic spread and the implementation of lockdown regulations across the globe.
Along with the major key players Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen, the research also includes a regional analysis and a national analysis with the most recent trends.
The global prevalence of disorders such as endometriosis, the primary cause of secondary dysmenorrhea, is increasing. Endometriosis affects an estimated 1 in 10 women throughout their fertile years, or around 176 million people globally, according to an article titled "Understanding Endometriosis—the Basics" published in July 2021. This element is predicted to have a substantial influence on market growth. As a result of the aforementioned factors, the nonsteroidal anti-inflammatory medicine category is predicted to considerably contribute to market expansion.
Read Full Research Report: https://marketresearchcommunity.com/dysmenorrhea-treatment-market/
North America is dominate the growth of the dysmenorrhea treatment market owing to the introduction of innovative products for treating the discomfort associated with primary and secondary dysmenorrhea. For example, in 2021, Pfizer Inc. and Myovant Sciences received FDA authorization for the assessment of a supplementary Novel Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) to treat mild to severe endometriosis pain. As a result of these reasons, the market for dysmenorrhea therapy in the United States is predicted to increase considerably over the forthcoming years.
The study is consolidated into major segments and further into sub-segments, such as by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), by Treatment Type (Non-steroidal Anti-inflammatory Drugs (NSAIDs), HormonalTherapy)to forecast the size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.
Contact us:
Market Research Community
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek